EDMA requests 5-yr transition to implement revised EU IVD framework
This article was originally published in RAJ Devices
Executive Summary
The European Commission's proposal to introduce a risk-based approach for classifying in vitro diagnostics as part of measures to overhaul the existing regulatory framework for this sector has been welcomed by IVD manufacturers even though it would require a "significant effort" on their part to adapt to the new requirements1.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.